Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2016
Filed with the SEC on Feb 6, 2017 and accepted by EDGAR at Feb 6, 2017, 08:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 9 months2016-04-01 to 2016-12-31 | $69.4m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2016-10-01 to 2016-12-31 | $10.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2016-04-01 to 2016-12-31 | $30.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2016-10-01 to 2016-12-31 | $13.5m | us-gaap:GrossProfit |
| Gross profit | 9 months2016-04-01 to 2016-12-31 | $39.3m | us-gaap:GrossProfit |
| Research and development | 3 months2016-10-01 to 2016-12-31 | $861.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2016-04-01 to 2016-12-31 | $2.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-10-01 to 2016-12-31 | $4.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2016-04-01 to 2016-12-31 | $11.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2016-10-01 to 2016-12-31 | $628.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2016-04-01 to 2016-12-31 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-10-01 to 2016-12-31 | $3.3m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months2016-04-01 to 2016-12-31 | $7.5m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2016-10-01 to 2016-12-31 | $0.84 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2016-04-01 to 2016-12-31 | $1.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-10-01 to 2016-12-31 | $0.88 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2016-04-01 to 2016-12-31 | $2.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-10-01 to 2016-12-31 | 3,868,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2016-04-01 to 2016-12-31 | 3,835,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Dividends paid | 9 months2016-04-01 to 2016-12-31 | $1.8m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2016-12-31 | $5.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-12-31 | $35.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $170.5m | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $22.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-12-31 | $76.7m | us-gaap:Liabilities |
| Long-term debt | At period end2016-12-31 | $50.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-12-31 | $3.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2016-12-31 | $93.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-17-001685. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.